updated 11/21/2007 11:34:03 AM ET 2007-11-21T16:34:03

GlaxoSmithKline PLC will buy heart drug specialist Reliant Pharmaceuticals Inc. for $1.65 billion in cash, the company said Wednesday.

GSK expects the transaction will add to earnings in 2008 and create additional value in following years.

Privately held Reliant develops specialty medicines combating heart disease and holds U.S. rights to Lovaza, a treatment for adult patients with very high levels of triglycerides.

Triglycerides are fatty substances in the blood associated with increased risks of coronary artery disease.

In the nine months ended Sept. 30 Reliant posted net sales of $206 million.

GlaxoSmithKline shares dipped 0.3 percent to 1,165 pence on the London Stock Exchange.

Copyright 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com